Transkaryotic(tktx) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transkaryotic(tktx)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who wrote (54)	7/7/2000 10:00:34 AM
From: Souze	of 122

Yes, the trial continues today. Here's the rest of that Dow Jones article, which the Boston Globe lopped off: Additionally, not all of the responsive cells generated stable amounts of the protein. Heartlein contrasted the results with Transkaryotic's gene-activated kidney cancer cells that were successful in making consistent amounts of erythropoietin. Counsel for Amgen poked at the strength of the testimony by focusing on the differences between Heartlein's experiment and Sugimoto's patents that would lead to dissimilar results: cells used for fusion, possible cell selection procedures, and stability data. Transkaryotic and Aventis ended the session with the introduction of expert witness Dr. Phillips W. Robbins, the American Cancer Society professor of biochemistry at Massachusetts Institute of Technology and professor of molecular and cell biology at Boston University. The court accepted his credentials as an expert witness in glycobiology. Attorneys will proceed with questioning of Robbins on Friday. -By Beth M. Mantz, Dow Jones Newswires; 201-938-5287 .

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next